Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
[This article belongs to Volume - 26, Issue - 03]

Fibroscan is an effective non-invasive tool to assess liver fibrosis changes in patients with chronic hepatitis B receiving different oral regimens

Liver fibrosis is a key prognostic factor for chronic hepatitis B (CHB), and an accurate assessment of the stage of liver fibrosis is pivotal for establishing effective management strategies. We aimed to assess liver fibrosis changes using Fibroscan in patients with CHB receiving different oral regimens. We included 485 patients with CHB: 339 were subjected to treatment, and 146 were excluded as they were in the immunotolerant phase and did not qualify for treatment. Of 339, 300 (88.5%) were HBe Ag− (Group A) and 39 (11.5%) were HBe Ag+ (Group B). Cases were initially assessed by conducting liver function tests, HBV quantitative PCR assay, HBe Ag detection, and Fibroscan and treated with lamivudine, entecavir, or tenofovir for at least 48 weeks. Fibroscan was conducted at 48 weeks of treatment. Both groups showed a significant reduction in alanine transaminase and aspartate transaminase levels after 48 weeks of treatment with lamivudine, entecavir, or tenofovir. Furthermore, they showed significant regression of liver fibrosis, as assessed using Fibroscan, after 48 weeks of treatment with lamivudine, entecavir, and tenofovir; patients receiving tenofovir and entecavir showed the highest percentage of reduction in liver stiffness (15.4% and 14.5% in Group A and 14.9% and 13.2% in Group B, respectively). Liver stiffness assessed using Fibroscan showed significant regression in patients with CHB receiving nucleos(t)ide analogs. Fibroscan can thus serve as an effective non-invasive tool to assess liver fibrosis changes in patients undergoing treatment for CHB, reducing the need for repeated biopsies.